Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition

Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet